Pembrolizumab with or without chemotherapy versus chemotherapy alone for patients with PD-L1-positive advanced gastric or gastroesophageal junction adenocarcinoma: Update from the phase 3 KEYNOTE-062 trial

被引：8
|
作者：
Wainberg, Zev A.
Shitara, Kohei
Van Cutsem, Eric
Wyrwicz, Lucjan
Lee, Keun Wook
Kudaba, Iveta
Garrido, Marcelo
Chung, Hyun Cheol Cheol
Lee, Jeeyun
Castro-Salguero, Hugo Raul
Mansoor, Wasat
Braghiroli, Maria Ignez
Karaseva, Nina
Goekkurt, Eray
Satake, Hironaga
Chao, Joseph
Kher, Uma
Shah, Sukrut
Bhagia, Pooja
Tabernero, Josep
机构：
[1] Univ Calif Los Angeles, Sch Med, Los Angeles, CA 90025 USA
[2] Natl Canc Ctr Hosp East, Kashiwa, Chiba, Japan
[3] Univ Hosp Gasthuisberg, Leuven, Belgium
[4] Katholieke Univ Leuven, Leuven, Belgium
[5] Maria Sklodowska Curie Mem Canc Ctr, Warsaw, Poland
[6] Inst Oncol, Warsaw, Poland
[7] Seoul Natl Univ, Bundang Hosp, Coll Med, Seongnam, South Korea
[8] Latvian Oncol Ctr Rakus Gailezers, Riga, Latvia
[9] Pontificia Univ Catolica Chile, Santiago, Chile
[10] Yonsei Univ, Coll Med, Yonsei Canc Ctr, Seoul, South Korea
[11] Samsung Med Ctr, Seoul, South Korea
[12] Los Angeles Med Grp, Guatemala City, Guatemala
[13] Christie Hosp NHS Trust, Manchester, Lancs, England
[14] Univ Sao Paolo, Inst Canc Sao Paolo, Sao Paulo, Brazil
[15] SPb SBHI Clin Oncol Dispensary, St Petersburg, Russia
[16] Hematol Oncol Practice Eppendorf, Hamburg, Germany
[17] Univ Canc Ctr Hamburg, Hamburg, Germany
[18] Gen Hosp, Kobe City Med Ctr, Kobe, Hyogo, Japan
[19] City Hope Comprehens Canc Ctr, Duarte, CA USA
[20] Merck & Co Inc, Kenilworth, NJ USA
[21] Hebron Univ Hosp HUVH, Barcelona, Spain
[22] UVic UCC, IOB Quiron, Inst Oncol VHIO, Barcelona, Spain
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 04期
关键词：
D O I：
10.1200/JCO.2022.40.4_suppl.243
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
243
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Pembrolizumab with or without chemotherapy versus chemotherapy for advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: The phase III KEYNOTE-062 study.
    Tabernero, Josep
    Van Cutsem, Eric
    Bang, Yung-Jue
    Fuchs, Charles S.
    Wyrwicz, Lucjan
    Lee, Keun Wook
    Kudaba, Iveta
    Garrido, Marcelo
    Chung, Hyun Cheol
    Salguero, Hugo Raul Castro
    Mansoor, Wasat
    Braghiroli, Maria Ignez Freitas Melro
    Goekkurt, Eray
    Chao, Joseph
    Wainberg, Zev A.
    Kher, Uma
    Shah, Sukrut
    Kang, SoonMo Peter
    Shitara, Kohei
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (18)
  • [2] Pembrolizumab or pembrolizumab plus chemotherapy versus standard of care chemotherapy in patients with advanced gastric or gastroesophageal junction adenocarcinoma: Asian subgroup analysis of KEYNOTE-062
    Satake, Hironaga
    Lee, Keun-Wook
    Chung, Hyun Cheol
    Lee, Jeeyun
    Yamaguchi, Kensei
    Chen, Jen-Shi
    Yoshikawa, Takaki
    Amagai, Kenji
    Yeh, Kun-Huei
    Goto, Masahiro
    Chao, Yee
    Lam, Ka-On
    Han, Shi Rong
    Shiratori, Shinichi
    Shah, Sukrut
    Shitara, Kohei
    [J]. JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2023, 53 (03) : 221 - 229
  • [3] Pembrolizumab with or without chemotherapy versus chemotherapy for first-line treatment of advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: The Phase 3 KEYNOTE-062 Study
    Tabernero, J.
    Van Cussem, E.
    Bang, Y.
    Fuchs, C.
    Wyrwicz, L.
    Lee, K.
    Kudaba, I.
    Garrido, M.
    Chung, C.
    Salguero, C. Castro
    Mansoor, W.
    Braghiroli, M.
    Goekkurt, E.
    Chao, J.
    Wainberg, Z.
    Kher, U.
    Shah, S.
    Karg, S.
    Shitara, K.
    [J]. ANNALS OF ONCOLOGY, 2019, 30 : 152 - +
  • [4] KEYNOTE-062:Phase 3 study of pembrolizumab alone or in combination with chemotherapy versus chemotherapy alone as first-line therapy for advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma.
    Tabernero, Josep
    Bang, Yung-Jue
    Fuchs, Charles S.
    Ohtsu, Atsushi
    Kher, Uma
    Lam, Baohoang
    Koshiji, Minori
    Van Cutsem, Eric
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [5] KEYNOTE-062: Phase III study of pembrolizumab (MK-3475) alone or in combination with chemotherapy versus chemotherapy alone as first-line therapy for advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma.
    Tabernero, Josep
    Bang, Yung-Jue
    Fuchs, Charles S.
    Ohtsu, Atsushi
    Kher, Uma
    Lam, Baohoang
    Koshiji, Minori
    Van Cutsem, Eric
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [6] Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial
    Shitara, Kohei
    Van Cutsem, Eric
    Bang, Yung-Jue
    Fuchs, Charles
    Wyrwicz, Lucjan
    Lee, Keun-Wook
    Kudaba, Iveta
    Garrido, Marcelo
    Chung, Hyun Cheol
    Lee, Jeeyun
    Castro, Hugo Raul
    Mansoor, Wasat
    Braghiroli, Maria Ignez
    Karaseva, Nina
    Caglevic, Christian
    Villanueva, Luis
    Goekkurt, Eray
    Satake, Hironaga
    Enzinger, Peter
    Alsina, Maria
    Benson, Al
    Chao, Joseph
    Ko, Andrew H.
    Wainberg, Zev A.
    Kher, Uma
    Shah, Sukrut
    Kang, S. Peter
    Tabernero, Josep
    [J]. JAMA ONCOLOGY, 2020, 6 (10) : 1571 - 1580
  • [7] Pembrolizumab versus paclitaxel for previously treated patients with PD-L1-positive advanced gastric or gastroesophageal junction cancer (GC): Update from the phase III KEYNOTE-061 trial.
    Fuchs, Charles S.
    Ozguroglu, Mustafa
    Bang, Yung-Jue
    Di Bartolomeo, Maria
    Mandala, Mario
    Ryu, Min-hee
    Fornaro, Lorenzo
    Olesinski, Tomasz
    Caglevic, Christian
    Chung, Hyun Cheol
    Muro, Kei
    Van Cutsem, Eric
    Elme, Anneli
    Thuss-Patience, Peter C.
    Chau, Ian
    Ohtsu, Atsushi
    Bhagia, Pooja
    Wang, Anran
    Shih, Chie-Schin
    Shitara, Kohei
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [8] Pembrolizumab versus paclitaxel for previously treated PD-L1-positive advanced gastric or gastroesophageal junction cancer: 2-year update of the randomized phase 3 KEYNOTE-061 trial
    Fuchs, Charles S.
    Ozguroglu, Mustafa
    Bang, Yung-Jue
    Di Bartolomeo, Maria
    Mandala, Mario
    Ryu, Min-Hee
    Fornaro, Lorenzo
    Olesinski, Tomasz
    Caglevic, Christian
    Chung, Hyun C.
    Muro, Kei
    Van Cutsem, Eric
    Elme, Anneli
    Thuss-Patience, Peter
    Chau, Ian
    Ohtsu, Atsushi
    Bhagia, Pooja
    Wang, Anran
    Shih, Chie-Schin
    Shitara, Kohei
    [J]. GASTRIC CANCER, 2022, 25 (01) : 197 - 206
  • [9] Pembrolizumab versus paclitaxel for previously treated PD-L1-positive advanced gastric or gastroesophageal junction cancer: 2-year update of the randomized phase 3 KEYNOTE-061 trial
    Charles S. Fuchs
    Mustafa Özgüroğlu
    Yung-Jue Bang
    Maria Di Bartolomeo
    Mario Mandala
    Min-Hee Ryu
    Lorenzo Fornaro
    Tomasz Olesinski
    Christian Caglevic
    Hyun C. Chung
    Kei Muro
    Eric Van Cutsem
    Anneli Elme
    Peter Thuss-Patience
    Ian Chau
    Atsushi Ohtsu
    Pooja Bhagia
    Anran Wang
    Chie-Schin Shih
    Kohei Shitara
    [J]. Gastric Cancer, 2022, 25 : 197 - 206
  • [10] Quality of life with first-line pembrolizumab for PD-L1epositive advanced gastric/gastroesophageal junction adenocarcinoma: results from the randomised phase III KEYNOTE-062 study
    Van Cutsem, E.
    Valderrama, A.
    Bang, Y. -J.
    Fuchs, C. S.
    Shitara, K.
    Janjigian, Y. Y.
    Qin, S.
    Larson, T. G.
    Shankaran, V.
    Stein, S.
    Norquist, J. M.
    Kher, U.
    Shah, S.
    Alsina, M.
    [J]. ESMO OPEN, 2021, 6 (04)
12345